Pfizer Inc.
NYSE:PFEDrug Manufacturers - General
-$0.71 today
- Market cap
- $159.94B
- Beta
- 0.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.32
- Dividend yield
- 6.82%
Volume 37.37M
Average 36.66M
PFE Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Pfizer Inc.NYSE: PFE
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue growth accelerates
Q2 FY2026 revenue of $15.03B rose 2.6% year over year, ahead of the -0.2% change in trailing-twelve-month revenue. Sequentially, it rose 4.0% from the prior quarter. Over 3 fiscal years it compounded at -14.8% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 18 analysts of $63.18B (+1.0%) for the fiscal year ending Dec 2026, a step up from the -1.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $15.03B+4.0% QoQ
- Last fiscal yearDec 2025
- $62.58B-1.6% YoY
- LTMJun 2026
- $63.7B-0.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.6% | -4.8% | -7.4 pp |
| 1 year | -1.6% | +1.0% | +2.6 pp |
| 3-year CAGR | -14.8% | -4.1% | +10.7 pp |
| 5-year CAGR | -2.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 62.58B USD
- Year-over-year change
- -1.6%
- 4-year CAGR
- -6.3%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 62.58B | -1.6% |
| FY2024 | 2024-12-31 | 63.63B | +6.8% |
| FY2023 | 2023-12-31 | 59.55B | -41.1% |
| FY2022 | 2022-12-31 | 101.18B | +24.5% |
| FY2021 | 2021-12-31 | 81.29B | — |
Revenue vs competitors
How PFE compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -0.2% is the lowest of 11, against a peer median of +6.2%.
- Over three fiscal years its annual growth of -14.8% compares with a peer median of +4.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $99.34B USD | +7.8% | +5.6% | |
| LTM Jun 2026 | $79.67B USD | +49.6% | +31.7% | |
| LTM Jun 2026 | $66.4B USD | +4.2% | +3.1% | |
| LTM Sep 2026 | $66.01B USD | +10.7% | +1.8% | |
| LTM Jun 2026 | $63.7B USD | -0.2% | -14.8% | |
| LTM Sep 2026 | $62.17B USD | +7.0% | +9.8% | |
| LTM Jun 2026 | $55.63B USD | +0.8% | +8.0% | |
| LTM Jun 2026 | $49.19B USD | +3.1% | +1.4% | |
| LTM Jun 2026 | €48.92B EUR | +13.4% | +4.8% | |
| LTM Jun 2026 | £33.2B GBP | +5.0% | +3.7% | |
| LTM Jun 2026 | $30.46B USD | +5.5% | +2.6% | |
| Peer median (excluding PFE) | — | +6.2% | +4.2% | |
Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 81.29B | 101.18B | 59.55B | 63.63B | 62.58B |
| Cost of Revenue | 30.82B | 34.34B | 24.95B | 17.85B | 16.07B |
| Gross Profit | 50.47B | 66.83B | 34.6B | 45.78B | 46.51B |
| Gross Margin | 62.1% | 66.1% | 58.1% | 71.9% | 74.3% |
| Research & Development | 13.83B | 11.43B | 10.68B | 10.82B | 10.44B |
| Selling, General & Admin | 12.7B | 13.68B | 14.77B | 14.73B | 13.79B |
| Operating Expenses | 30.23B | 28.71B | 30.18B | 30.84B | 29.11B |
| Depreciation & Amortization | 5.19B | 5.06B | 6.29B | 7.01B | 6.59B |
| EBITDA | 30.79B | 41.03B | 9.56B | 18.13B | 16.78B |
| EBITDA Margin | 37.9% | 40.6% | 16.0% | 28.5% | 26.8% |
| Operating Income | 20.24B | 38.12B | 4.42B | 14.94B | 17.41B |
| Operating Margin | 24.9% | 37.7% | 7.4% | 23.5% | 27.8% |
| Interest Income | 36M | 251M | 1.62B | 545M | 603M |
| Interest Expense | 1.29B | 1.24B | 2.21B | 3.09B | 2.67B |
| Other Income / Expenses | 4.08B | (3.39B) | (3.36B) | (6.92B) | (9.89B) |
| Income Before Tax | 24.31B | 34.73B | 1.06B | 8.02B | 7.52B |
| Pre-Tax Margin | 29.9% | 34.3% | 1.8% | 12.6% | 12.0% |
| Income Tax Expense | 1.85B | 3.33B | (1.12B) | (28M) | (266M) |
| Net Income | 21.98B | 31.37B | 2.12B | 8.03B | 7.77B |
| Net Margin | 27.0% | 31.0% | 3.6% | 12.6% | 12.4% |
| EPS (Basic) | 3.95 | 5.59 | 0.38 | 1.42 | 1.36 |
| EPS (Diluted) | 3.88 | 5.47 | 0.37 | 1.41 | 1.36 |
| Weighted Avg Shares | 5.6B | 5.61B | 5.64B | 5.66B | 5.68B |
| Weighted Avg Shares (Diluted) | 5.71B | 5.73B | 5.71B | 5.7B | 5.69B |
Pfizer Inc.
NYSE:PFE
Intrinsic Alpha fair value
Locked
Current Price
$28.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.